Reuters logo
BRIEF-Immune Design gets positive FDA feedback on Phase 3 clinical trial design for CMB305
2017年10月16日 / 晚上8点42分 / 1 个月前

BRIEF-Immune Design gets positive FDA feedback on Phase 3 clinical trial design for CMB305

Oct 16 (Reuters) - Immune Design Corp

* Immune Design announces positive FDA feedback on Phase 3 clinical trial design for CMB305 in synovial sarcoma patients

* Immune Design- plans to initiate pivotal Phase 3 trial to support a Biologics License Application (BLA) for CMB305 in patients with synovial sarcoma​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below